CA2895162C - Methods and compositions for inhibiting cnksr1 - Google Patents

Methods and compositions for inhibiting cnksr1 Download PDF

Info

Publication number
CA2895162C
CA2895162C CA2895162A CA2895162A CA2895162C CA 2895162 C CA2895162 C CA 2895162C CA 2895162 A CA2895162 A CA 2895162A CA 2895162 A CA2895162 A CA 2895162A CA 2895162 C CA2895162 C CA 2895162C
Authority
CA
Canada
Prior art keywords
cancer
compound
kras
c4alkyl
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2895162A
Other languages
English (en)
French (fr)
Other versions
CA2895162A1 (en
Inventor
D. Lynn Kirkpatrick
Martin INDARTE
Nathan T. Ihle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PHUSIS THERAPEUTICS Inc
Original Assignee
PHUSIS THERAPEUTICS Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PHUSIS THERAPEUTICS Inc filed Critical PHUSIS THERAPEUTICS Inc
Publication of CA2895162A1 publication Critical patent/CA2895162A1/en
Application granted granted Critical
Publication of CA2895162C publication Critical patent/CA2895162C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
CA2895162A 2012-12-14 2013-12-16 Methods and compositions for inhibiting cnksr1 Active CA2895162C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261737658P 2012-12-14 2012-12-14
US61/737,658 2012-12-14
PCT/US2013/075505 WO2014093988A2 (en) 2012-12-14 2013-12-16 Methods and compositions for inhibiting cnksr1

Publications (2)

Publication Number Publication Date
CA2895162A1 CA2895162A1 (en) 2014-06-19
CA2895162C true CA2895162C (en) 2021-03-09

Family

ID=50935099

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2895162A Active CA2895162C (en) 2012-12-14 2013-12-16 Methods and compositions for inhibiting cnksr1

Country Status (7)

Country Link
US (1) US9340532B2 (cg-RX-API-DMAC7.html)
EP (1) EP2931280B1 (cg-RX-API-DMAC7.html)
JP (1) JP6357292B2 (cg-RX-API-DMAC7.html)
AU (1) AU2013358876B2 (cg-RX-API-DMAC7.html)
CA (1) CA2895162C (cg-RX-API-DMAC7.html)
MX (2) MX372739B (cg-RX-API-DMAC7.html)
WO (1) WO2014093988A2 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6357292B2 (ja) 2012-12-14 2018-07-11 フューシス セラピューティクス、インク. Cnksr1を阻害するための方法及び組成物
CA2983260C (en) * 2015-04-20 2024-01-23 Phusis Therapeutics, Inc. Sulfonamide compounds, compositions and methods for inhibiting cnksr1
US20190367457A1 (en) 2016-12-30 2019-12-05 Mitobridge, Inc. Oxopyridine derivatives useful as aminocarboxymuconate semialdehyde decarboxylase (acmsd) inhibitors
CN110698411B (zh) * 2018-07-09 2023-05-09 四川大学 一类4-(胺烷基)酞嗪-1-酮类化合物、其制备方法和用途
EP4188383A4 (en) * 2020-07-28 2025-01-08 Mirati Therapeutics, Inc. SOS1 INHIBITORS
WO2022187804A1 (en) * 2021-03-02 2022-09-09 Icahn School Of Medicine At Mount Sinai Benzoxazolone inhibitors of inflammasomes
TW202319375A (zh) * 2021-08-19 2023-05-16 美商安進公司 用於製備丙烯酸酯化合物之無鈀方法
WO2024192873A1 (zh) * 2023-03-20 2024-09-26 杭州天玑济世生物科技有限公司 一类具有萘胺结构的小分子化合物的用途
CN116444477B (zh) * 2023-04-04 2026-01-02 宁波九胜创新医药科技有限公司 一种溴代胡椒环羧酸的制备方法及其用途

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA775563A (en) 1968-01-09 Frank W. Horner Limited Hypoglycemic thiadiazoles
GB828963A (en) 1956-08-03 1960-02-24 Rhone Poulenc Sa Pharmaceutical compositions containing 2-p-aminobenzenesulphonamido-5-t-butyl-1, 3, 4-thiadiazole
US3821222A (en) 1971-11-22 1974-06-28 Chevron Res Hydrocarbyl sulfenylmercapto pyrimidines
US4017489A (en) 1975-07-10 1977-04-12 The Goodyear Tire & Rubber Company Process of preparing unsymmetrical disulfides
DE2556011A1 (de) 1975-12-12 1977-06-23 Merck Patent Gmbh Disulfide
IE47592B1 (en) * 1977-12-29 1984-05-02 Ici Ltd Enzyme inhibitory phthalazin-4-ylacetic acid derivatives, pharmaceutical compositions thereof,and process for their manufacture
GB2152497B (en) 1983-11-28 1987-08-05 Otsuka Kagaku Kk Process for the preparation of azetidinone derivatives
FR2573077B1 (fr) 1984-11-13 1987-02-13 Sanofi Sa Nouveaux derives thiosulfonates, leur procede de preparation ainsi que les compositions pharmaceutiques les contenant
US4939140A (en) * 1985-11-07 1990-07-03 Pfizer Inc. Heterocyclic oxophthalazinyl acetic acids
US4990523A (en) 1989-06-19 1991-02-05 A. H. Robins Company, Incorporated Treatment of chronic inflammatory joint disease with arylsulfonamides
GB9507415D0 (en) * 1994-06-08 1995-05-31 Zylepsis Ltd Production and uses of caffeic acid and derivatives thereof
US6139875A (en) 1998-09-29 2000-10-31 Eastman Chemical Company Aqueous enteric coating composition and low gastric permeability enteric coating
FR2815032B1 (fr) 2000-10-10 2003-08-08 Pf Medicament Nouveaux derives d'aminophenyle piperazine ou d'amino phenyle piperide inhibiteurs de proteines prenyl transferase ainsi que leurs preparations
JP2004527531A (ja) 2001-04-10 2004-09-09 メルク エンド カムパニー インコーポレーテッド 癌を治療する方法
KR100957516B1 (ko) * 2001-08-15 2010-05-14 이코스 코포레이션 2h-프탈라진-1-온 및 이것의 사용 방법
GB0205693D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
AU2003226301A1 (en) 2002-04-08 2003-10-20 Merck And Co., Inc. Method of treating cancer
GB0215823D0 (en) * 2002-07-09 2002-08-14 Astrazeneca Ab Quinazoline derivatives
US20040102360A1 (en) 2002-10-30 2004-05-27 Barnett Stanley F. Combination therapy
EP1644390B1 (en) 2003-06-24 2011-04-20 Isis Innovation Limited Reagents and methods for the formation of disulfide bonds and the glycosylation of proteins
CA2531418A1 (en) 2003-07-08 2005-01-20 Novartis Ag Benzenesulfonylamino compounds and pharmaceutical compositions containing these compounds
EP1751225B1 (en) 2004-03-19 2009-08-05 The Tapemark Company Thermoplastic films and methods for making
JP2007530589A (ja) 2004-03-26 2007-11-01 アンフォラ ディスカバリー コーポレーション 特定のトリアゾールを基礎とする化合物、組成物、およびそれらの使用
SE0402635D0 (sv) 2004-10-29 2004-10-29 Astrazeneca Ab Chemical compounds
DE102005011822A1 (de) * 2005-03-15 2006-09-21 Merck Patent Gmbh Phthalazinone
DE602006018172D1 (de) 2005-10-06 2010-12-23 Sanofi Aventis Cyclische n-ä1,3,4ü-thiadiazol-2-yl-benzsulfonamide, verfahren zu deren herstellung und deren verwendung als arzneimittel
US20070213378A1 (en) 2006-03-10 2007-09-13 Lymphosign Inc. Compounds for modulating cell proliferation, compositions and methods related thereto
KR20150038395A (ko) 2006-04-04 2015-04-08 더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 키나제 길항물질
EP2104489A2 (en) 2006-12-26 2009-09-30 FemmePharma Holding Company, Inc. Topical administration of danazol
EP2291349A2 (en) 2008-04-14 2011-03-09 The Board of Regents of The University of Texas System Small molecule inhibitors of the pleckstrin homology domain and methods for using same
WO2010085968A1 (en) * 2008-12-30 2010-08-05 European Molecular Biology Laboratory (Embl) Toluidine sulfonamides and their use as hif-inhibitors
JP5756457B2 (ja) * 2009-04-06 2015-07-29 アジオス ファーマシューティカルズ, インコーポレイテッド ピルビン酸キナーゼm2調節剤、治療組成物および関連する使用方法
US20120189670A1 (en) 2009-09-14 2012-07-26 Kirkpatrick D Lynn Pharmaceutical compositions and formulations including inhibitors of the pleckstrin homology domain and methods for using same
CA2832100A1 (en) * 2011-04-05 2012-10-11 Vertex Pharmaceuticals Incorporated Aminopyrazine compounds useful as inhibitors of tra kinase
JP6357292B2 (ja) 2012-12-14 2018-07-11 フューシス セラピューティクス、インク. Cnksr1を阻害するための方法及び組成物

Also Published As

Publication number Publication date
EP2931280A2 (en) 2015-10-21
US9340532B2 (en) 2016-05-17
WO2014093988A2 (en) 2014-06-19
JP6357292B2 (ja) 2018-07-11
MX393754B (es) 2025-03-24
MX372739B (es) 2020-05-06
EP2931280B1 (en) 2018-02-14
JP2016508969A (ja) 2016-03-24
EP2931280A4 (en) 2016-06-01
US20150307482A1 (en) 2015-10-29
WO2014093988A3 (en) 2014-08-07
AU2013358876B2 (en) 2018-05-10
CA2895162A1 (en) 2014-06-19
AU2013358876A1 (en) 2014-06-19
MX2015007608A (es) 2016-04-13

Similar Documents

Publication Publication Date Title
EP2931280B1 (en) Methods and compositions for inhibiting cnksr1
JP7789832B2 (ja) がんを治療するための組成物及び方法
Li et al. Discovery of N 1-(4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7 H-pyrrolo [2, 3-d] pyrimidin-2-yl) amino) phenyl)-N 8-hydroxyoctanediamide as a Novel Inhibitor Targeting Cyclin-dependent Kinase 4/9 (CDK4/9) and Histone Deacetlyase1 (HDAC1) against Malignant Cancer
KR102057358B1 (ko) Tor 키나제 억제제를 사용한 암의 치료
JP5711813B2 (ja) βセクレターゼ(BACE)の阻害剤として有用な5,6−ジヒドロ−2H−[1,4]オキサジン−3−イル−アミン誘導体
ES2668279T3 (es) Tratamiento del cáncer con inhibidores de la cinasa TOR
ES2678250T3 (es) Tratamiento del cáncer con inhibidores de quinasa TOR
RU2646758C2 (ru) Гетероарил пиридоны и азапиридоны с электрофильной функциональностью
US10183019B2 (en) Treatment of cancer with dihydropyrazino-pyrazines
ES2780382T3 (es) Derivados de pirazolopirimidina
FR2929851A1 (fr) Molecules inhibant une voie metabolique impliquant la proteine tyrosine kinase syk et procede d'identification de ces molecules
BR122021004509B1 (pt) Sais de inibidor de pi3k e processos para seu preparo
JP2019508404A (ja) 癌患者の層別化および癌治療のための化合物、組成物および方法
JP6708849B1 (ja) ピロロピリジン誘導体化合物、その製造方法及びこれを有効成分として含有するタンパク質キナーゼ関連疾患の予防または治療のための薬学的組成物
TWI458730B (zh) 新穎2,3-二氫-1H-咪唑并{1,2-a}嘧啶-5-酮衍生物,其製法及其醫藥用途
JP2024535128A (ja) 新規治療
CA2983260C (en) Sulfonamide compounds, compositions and methods for inhibiting cnksr1
US20230144901A1 (en) Sortilin antagonists for use in the treatment of diabetic retinopathy
US20240391928A1 (en) Compositions for the treatment of food and chemical addiction and methods of making and using same
JP2023513016A (ja) Nek2阻害剤としてのアミノピリミジニルアミノベンゾニトリル誘導体
BR112017018312B1 (pt) Sais de inibidor de pi3k, composições que as compreende, seu uso, processos para seu preparo e método de inibição de uma atividade de uma quinase pi3k

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20181214

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241206

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241206

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241206

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD

Year of fee payment: 12

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251124

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251124